Compare · BLFS vs SLNO
BLFS vs SLNO
Side-by-side comparison of BioLife Solutions Inc. (BLFS) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLFS and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 1.9x BLFS ($1.42B).
- Over the past year, BLFS is up 39.8% and SLNO is down 39.2% - BLFS leads by 78.9 points.
- BLFS has been more active in the news (8 items in the past 4 weeks vs 1 for SLNO).
- SLNO has more recent analyst coverage (12 ratings vs 8 for BLFS).
- Company
- BioLife Solutions Inc.
- Soleno Therapeutics Inc.
- Price
- $29.11-3.83%
- $53.02+0.08%
- Market cap
- $1.42B
- $2.76B
- 1M return
- +10.60%
- +0.76%
- 1Y return
- +39.75%
- -39.20%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 1
- Recent ratings
- 8
- 12
BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest BLFS
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 844 shares, decreasing direct ownership by 0.39% to 213,249 units (SEC Form 4) (withholding obligation)
- EVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 516 shares, decreasing direct ownership by 0.13% to 388,460 units (SEC Form 4) (for tax liability)
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 293 shares, decreasing direct ownership by 0.18% to 162,649 units (SEC Form 4) to cover taxes
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 470 shares, decreasing direct ownership by 0.29% to 162,942 units (SEC Form 4) (tax liability)
- Chief Technology Officer Werner Sean covered exercise/tax liability with 420 shares, decreasing direct ownership by 0.87% to 47,831 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 937 shares, decreasing direct ownership by 0.44% to 214,093 units (SEC Form 4) to cover taxes
- EVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 564 shares, decreasing direct ownership by 0.14% to 388,976 units (SEC Form 4) to cover taxes
- President and CEO De Greef Roderick covered exercise/tax liability with 2,775 shares, decreasing direct ownership by 0.38% to 730,971 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 1,026 shares, decreasing direct ownership by 0.47% to 215,030 units (SEC Form 4) (withholding obligation)
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 356 shares, decreasing direct ownership by 0.22% to 163,412 units (SEC Form 4) (tax withholding)
Latest SLNO
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)